Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共5页
• 作者

  Levis Mark J.; Perl Alexander E.; Altman Jessica K.; Cortes Jorge E.; Smith Catherine C.; Baer Maria R.; Claxton David F.; Jurcic Joseph G.; Ritchie Ellen K.; Strickland Stephen A.; Tibes Raoul; Hill Jason E.; Rosales Matt; Bahceci Erkut;

  展开▼
• 作者单位

  Johns Hopkins Univ Sidney Kimmel Comprehens Canc Ctr Baltimore MD USA;

  Univ Penn Abramson Canc Ctr Philadelphia PA 19104 USA;

  Northwestern Univ Feinberg Sch Med Robert H Lurie Comprehens Canc Ctr Chicago IL 60611 USA;

  Univ Texas MD Anderson Canc Ctr Dept Leukemia Houston TX 77030 USA;

  Univ Calif San Francisco San Francisco CA 94143 USA;

  Univ Maryland Greenebaum Canc Ctr Baltimore MD 21201 USA;

  Penn State Milton S Hershey Med Ctr Hershey PA USA;

  Columbia Univ Med Ctr New York NY USA;

  Weill Cornell Med Coll New York NY USA;

  Vanderbilt Ingram Canc Ctr Nashville TN USA;

  NYU Laura &

  Isaac Perlmutter Canc Ctr Langone Hlth New York NY USA;

  Astellas Pharma Global Dev Northbrook IL USA;

  Astellas Pharma Global Dev Northbrook IL USA;

  Astellas Pharma Global Dev Northbrook IL USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词